Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.65 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.54 |
| ▸ | WIZ | O95785 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046071 | 1.00 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL20211856 | 1.00 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL20211890 | 1.00 | CRBN (0.65) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL22581027 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL20211892 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL30720151 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| Hydrochloric Acid SCHEMBL30433803 | 0.99 | CRBN (0.64) | CRBNIKZF2WIZCSNK1A1IKZF1 | |
| SCHEMBL20231641 | 0.97 | CRBN (0.61) | CRBNIKZF2WIZCSNK1A1 | |
| SCHEMBL31131377 | 0.97 | CRBN (0.61) | CRBNIKZF2WIZCSNK1A1 | |
| Hydrochloric Acid SCHEMBL30906265 | 0.96 | CRBN (0.60) | CRBNIKZF2WIZCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071478-A | Compound for targeted degradation of GLI1 protein and medicinal application thereof | 苏州大学 | 2026-05-22 | — | — | CN | disclosed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4722209-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Shenogen Pharma Group (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709486-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4638454-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | Celgene Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-115697990-A | Indazole-based compounds and related methods of use | 阿维纳斯企业公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022251224-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022237904-A1 | NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| US-20220348595-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTORS | ENDOTARGET INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022217010-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTORS | ENDOTARGET INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-114867727-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | CRBN 429/4885IKZF2 3994/4885WIZ 4597/4885 |
| US-20220348595-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ESTROGEN RECEPTORS | ESR1, ESR2, ESRRG | CRBN 6/4885IKZF2 2019/4885WIZ 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.